Pharmacokinetics and Biodistribution of 89 Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma

• Published in: Molecular pharmaceutics Vol. 20; no. 3; pp. 1549 - 1563
• Main Authors: Ghosh, Saikat, Fletcher, Nicholas L, Huda, Pie, Houston, Zachary H, Howard, Christopher B, Lund, Maria E, Lu, Yanling, Campbell, Douglas H, Walsh, Bradley J, Thurecht, Kristofer J
• Format: Journal Article
• Language: English
• Published: United States 06.03.2023
• Subjects: Antibodies, Monoclonal - pharmacokinetics; Cell Line, Tumor; Glioblastoma; Glypicans; Humans; Immunoglobulin Fragments; Neoplasm Recurrence, Local; Positron-Emission Tomography - methods; Tissue Distribution; Zirconium; pharmacokinetics; antibody fragments; biodistribution; glioblastoma; glypican-1; PET

Glioblastoma (GBM) is the most aggressive form of primary brain cancer, accounting for about 85% of all primary central nervous system (CNS) tumors. With standard treatment strategies like surgery, radiation, and chemotherapy, the median survival time of patients with GBM is only 12-15 months from d...